RT Journal Article
SR Electronic
T1 A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.30.22277092
DO 10.1101/2022.06.30.22277092
A1 Subotheni Thavaneswaran
A1 Frank P Lin
A1 Maya Kansara
A1 John P Grady
A1 David Espinoza
A1 Anthony M Joshua
A1 Peter Grimison
A1 Paul Craft
A1 Rasha Cosman
A1 Chee Lee
A1 Kathleen Harwood
A1 Sarah Chinchen
A1 Theresa Corpuz
A1 Mandy Ballinger
A1 Lucille Sebastian
A1 John Simes
A1 David Thomas
YR 2022
UL http://medrxiv.org/content/early/2022/07/03/2022.06.30.22277092.abstract
AB Immune checkpoint blockade impedes the negative regulatory signals for T-cell response and permits more effective immune detection and eradication of cancer cells. This single-arm phase II clinical trial (ACTRN12616001019493) within the Molecular Screening and Therapeutics (MoST) program evaluates the clinical activity and safety of combination immunotherapy with durvalumab and tremelimumab in patients with advanced cancers, prioritsing rare cancers (<6 per 100,000 annual incidence) and patients having failed standard treatments for their cancer type.Methods Eligible patients were determined by the molecular tumour board based on the absence of actionable genomic findings (n=64) and biomarker enriched (n=48) at screening. Patients received durvalumab 1500 mg and tremelimumab 75 mg every four weeks for 4 cycles, followed by durvalumab alone for another 9 cycles. The primary endpoint was progression-free survival at 6 months (PFS6) and secondary endpoints included objective response, time to progression (TTP) on trial to TTP on prior therapy (TTP2/TTP1>1.3), overall survival and treatment tolerability.Results Between December 2016 and 2019, 112 patients were enrolled on the study. There was a female predominance (55%), most had an ECOG performance status of 0 (66%), aged <65 years (75%), with rare cancers (84%). The PFS6 rate was 32% (95% CI 23 to 40%); 16 of 112(14%) achieved an objective response; TTP2/TTP1>1.3 for 22 of 63 (35%) patients with an evaluable ratio; median overall survival 11.9 months (95% CI 11.0 to 14.8), and there were no new safety concerns. High tumour cell PD-L1 correlated with improved PFS and OS and TMB with PFS alone. More PD-1+CD4+ T-cells and circulating follicular T-helper (cTfh) cells at baseline were strongly associated with better PFS and OS.Conclusion Durvalumab plus tremelimumab demonstrated a signal of clinical activity in treatment-refractory patients with rare cancers. A PFS6 of 32% and 35% of patients achieving a TTP2/TTP1>1.3 suggests an improved disease trajectory on trial. Translational correlates provided insights into biological associations with clinical outcomes across tumour types.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12616001019493Funding StatementThe Molecular Screening and Therapeutics (MoST) Program is funded by the Commonwealth, as well as the NSW governments via the Office of Health and Medical Research, NSW. We kindly acknowledge Astra Zeneca for funding and provision of durvalumab and tremelimumab for the trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:St Vincent's Hospital Human Research Ethics Committee, 390 Victoria Street, Darlinghurst NSW 2010.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.